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Macrophages inflammatory cytokines/chemokines in prostate cancer (PCa) 
microenvironment may go through androgen receptor (AR) signaling to influence PCa progression: 
macrophages induce tumorigenesis by the alteration of AR-CCL4 signaling and can be interrupted 
by AR-degradation enhancer ASC-J9®. Androgen deprivation therapy with anti-androgens 
enhances CCL2-pSTAT3 signaling to promote metastasis and ASC-J9® can inhibit CCL2-pSTAT3 
signaling to suppress PCa metastasis. Targeting inflammatory cytokines-AR signaling with 




Prostate cancer (PCa) is the most frequently diagnosed cancer in men and the second 
leading cause of cancer death in the United States (1). Although androgen deprivation therapy 
(ADT) is useful for advanced PCa, its effects are limited because PCa changes to a 
castration-resistant phenotype over 1-2 years of therapy. Early studies demonstrated that ADT with 
anti-androgens to prevent/suppress androgens binding to AR in whole body promoted the 
development of invasive PCa, suggesting therapeutic suppressing androgens binding to AR may 
elicit unwanted signals that may favor the progression of surviving PCa cells to the advanced stage 
(2). In another study, targeting AR signaling led to suppress the wound-healing process by 
modulating macrophage infiltration with alterations of cytokine expression profiles (3). Since gene 
signatures of wound healing responses are similar to genes identified in the progressive breast 
cancer with high metastatic potential (4), we studied the potential linkage of AR signaling and 
inflammatory responses from infiltrating macrophages and their impact on the PCa progression in 
this review. 
 
Infiltrating macrophages promote prostate tumorigenesis 
Infiltrating macrophages are a key component of inflammation during prostate tumorigenesis. 
Fang et al first demonstrated that co-culturing of immortalized prostate epithelial cells with 
macrophages induces prostate tumorigenesis (5). Clinical sample surveys confirmed the number 
of macrophages was significantly increased in high-grade prostatic intraepithelial neoplasia (PIN) 
or PCa lesions compared with those in benign prostate on human prostate tissue. 
Macrophages-induced prostate tumorigenesis involved the alteration of signaling of macrophage 
AR-inflammatory chemokine CCL4–STAT3 activation as well as epithelial-to-mesenchymal 
transition (EMT) and down-regulation of p53/PTEN tumor suppressors. PTEN+/- mice lacking 
macrophage AR developed far fewer PIN lesions. CCL4-neutralizing antibody effectively blocked 
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macrophage-induced prostate tumorigenic signaling and targeting AR via a newly identidied 
AR-degradation enhancer ASC-J9® reduced CCL4 expression and PCa tumor growth in 
xenografted mouse model. Importantly, CCL4 up-regulation was associated with increased snail 
expression and down-regulation of p53/PTEN in high-grade PIN and PCa.  
Together, these results demonstrated that AR-CCL4 signaling in the prostate tumor 
microenvironment might become the potential therapeutic targets to effectively battle the 
inflammation-associated PCa initiation. 
 
Suppression of AR via AR-siRNA induces CCL2 that leads to promote PCa metastasis 
We next tested our hypothesis that suppressing AR function via AR-siRNA in PCa might 
simultaneously trigger undesirable inflammatory signals that could enhance the macrophage 
infiltration to stimulate progression of PCa (6). Targeting AR with AR-siRNA in macrophage THP-1 
cells enhances the migration of macrophages towards PCa. Similarly, suppression PCa AR with 
AR-siRNA also enhances the recruitment of macrophage THP-1 cells. Mechanism dissection 
revealed that AR silencing via AR-siRNA in either macrophages or PCa cells induces the 
expression of CCL2 and CCL2-dependent STAT3 activation that may then enhance the EMT 
signaling to promote the PCa cell invasion. Pharmacologic interruption of the CCL2/CCR2-STAT3 
signaling suppresses the EMT and PCa cell invasion, suggesting a newly identified signaling from 
CCL2/CCR2 to pSTAT3 to EMT may play key roles to promote the PCa cell invasion.  
Knocking out macrophage AR in TRAMP PCa mouse model leads to promote the PCa 
metastasis via induction of CCL2 and macrophage infiltration. Combined targeting of PCa AR and 
anti-CCL2/CCR2 signaling results in better suppression of PCa growth with reduced metastasis 
than targeting PCa AR alone in a xenografted PCa mouse model.  
Human PCa tissue microarray analysis also reveals that PCa patients’ outcome may become 
much worse when their PCa were staining CCL2-positive as compared to those PCa patients with 
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CCL2-negative, suggesting that CCL2 may play key role in promotion the PCa progression. 
Together, these results may provide a novel therapeutic approach to better battle PCa 
progression and metastasis at the castration resistant stage via the combination of targeting AR 
with AR-siRNA and anti-CCL2/CCR2-STAT3 signaling. 
 
ADT with anti-androgens enhances PCa metastasis via enhanced the macrophage 
infiltration and STAT3-CCL2 signaling 
Previous meta-analysis demonstrated that ADT using luteinizing hormone-releasing hormone 
(LH-RH) agonist plus anti-androgens improves overall survival rate of PCa patients compared with 
ADT using LH-RH agonist mono-therapy (7). Interesting, using Bicalutamide (Casodex), a 
currently used non-steroidal anti-androgen and/or Enzalutamide, formerly called MDV3100, a 
newly developed more powerful anti-androgen with better efficacy to suppress PCa at the 
castration-resistant stage (8), we found they could promote PCa cell invasion via increase the 
macrophage migration to PCa cells (9). Mechanism dissection revealed that bicalutamide and 
enzalutamide reduced the AR-mediated PIAS3 expression with enhanced the pSTAT3-CCL2 
signaling. Suppression of pSTAT3-CCL2/CCR2 signaling reversed the bicalutamide- or 
enzalutamide-induced macrophage migration and PCa cell invasion. Importantly, ASC-J9® 
suppressed both macrophage migration and subsequent PCa cell invasion through regulation of 
pSTAT3-CCL2 signaling via an AR-independent pathway to directly suppress the STAT3 
phosphorylation/activation. These in vitro cell lines findings were confirmed in the in vivo mouse 
model with orthotopically injected PCa cells.  
Together, these results may raise the potential concern about the currently used ADT with 
anti-androgens that promotes PCa metastasis and may provide a new and better therapeutic 
approach via using ASC-J9® alone or a combinational therapy that simultaneously targets 
androgen/AR signaling and PIAS3-pSTAT3-CCL2 signaling to better battle PCa growth and 
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metastasis at castration-resistant stage. 
 
Conclusions 
 Macrophages may play key roles from beginning of PCa initiation to later metastasis via 
regulating AR signaling and/or its modulated inflammatory cytokines/chemokines (Figure 1). ADT 
with anti-androgens may enhance macrophages-associated inflammatory cytokines-AR signaling 
to promote PCa metastasis. A combinational ADT therapy with additional drugs to target those 
macrophages-associated inflammatory cytokines may be needed to better battle PCa progression. 
Alternatively, using a newly developed AR degradation enhancer ASC-J9® to simultaneously 
suppress AR and those macrophages-associated inflammatory cytokines with less toxicity or side 
effects (10) may become a new therapy to better battle PCa in the future. 
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Figure legend 
Fig. 1. Vicious cycle between PCa cells and macrophages through chemokine activation: 
Infiltrating macrophages and inflammatory cytokine, CCL4, play a key role during PCa initiation 
through the activation of AR-CCL4-STAT3 axis (arrows with broken line). As bicalutamide or 
enzalutamide reduce the AR-mediated PIAS3 expression and enhanced the pSTAT3-CCL2 
pathway, these anti-androgens promote macrophage migration to PCa cells that consequently led 
to enhanced PCa cell invasion (white arrows). Suppressing macrophage AR function 
simultaneously triggers undesirable inflammatory signals that prompt macrophage infiltration and 
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